VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Incorpor ated in H ong Kong with limi ted liabi lity) (Stock co de: 1093) VOLUNTARY ANNOUNCEMENT BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Investigational New Drug (IND) application for JMT106 (the “Product”), a bispecific fusion protein drug developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trial in the U.S. The Product is an anti-tumor drug. The indication for this clinical trial approval is GPC3-positive solid tumors. The Product is a bispecific fusion protein drug that targets GPC3 and interferon receptors, killing tumor cells through GPC3-targeted antibodies and simultaneously activating the immune regulation of the tumor microenvironment mediated by interferon receptors. GPC3 is specifically and highly expressed in various solid tumors such as hepatocellular carcinoma, squamous cell carcinoma of the lung and ovarian cancer. Preclinical studies have demonstrated that the Product has a broad variety of indications, showing significant anti-tumor effects in malignant tumor models, such as liver cancer, lung cancer and ovarian cancer, as well as good safety profile, which provides a promising clinical development value. By order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 15 January 2024 - 1 - As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors. - 2 -

The release as fetched from its publisher. irasia.com ↗